VCM
DNA icon

Versant Capital Management’s Ginkgo Bioworks DNA Stock Holding History

Versant Capital Management’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-32
Closed -$467 – 2667
2025
Q3 		$467 Hold
32
– – ﹤0.01% 2573
2025
Q2 		$360 Buy
+32
New +$248 ﹤0.01% 2570
2024
Q1 		– Sell
-4
Closed -$264 – 1892
2023
Q4 		$264 Hold
4
– – ﹤0.01% 1816
2023
Q3 		$282 Hold
4
– – ﹤0.01% 1799
2023
Q2 		$292 Buy
+4
New +$237 ﹤0.01% 1937

Other funds holding DNA

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Versant Capital Management's DNA Position: Q4 2025 in Review

Versant Capital Management sold out of Ginkgo Bioworks (DNA) in Q4 2025, closing a stake of 32 shares — an estimated $467 sold.

Versant Capital Management first reported a position in DNA in Q2 2023 and held it in 5 quarters. The position peaked at $467 in Q3 2025. 181 funds tracked by Wall St. Rank hold DNA as of Q4 2025.

  • Versant Capital Management reported no remaining Ginkgo Bioworks position as of Q4 2025 after selling out during the quarter.
  • Versant Capital Management sold 32 Ginkgo Bioworks shares in Q4 2025, an estimated $467.
  • Versant Capital Management first reported a position in Ginkgo Bioworks in Q2 2023 and held it in 5 quarters.
  • Versant Capital Management's Ginkgo Bioworks position peaked at $467 in Q3 2025.
  • 181 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q4 2025.

Based on Versant Capital Management's 13F filing for Q4 2025, filed 8 Jan 2026.